AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)

Journal of Hepatology

Volumn 52, Issue 1, 2010, Pages 79-87

  Huynh, Hung ^a   Ngo, Van Chanh ^a   Koong, Heng Nung ^b   Poon, Donald ^b   Choo, Su Pin ^b   Toh, Han Chong ^b   Thng, Choon Hua ^b   Chow, Pierce ^c   Ong, Hock Soo ^c   Chung, Alexander ^c   Goh, Boon Cher ^d   Smith, Paul D ^e   Soo, Khee Chee ^a  

^a Humphrey Oei Institute of Cancer Research   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Combined therapy; Growth inhibition; HCC xenografts

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; SOMATOMEDIN C RECEPTOR; SORAFENIB;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; BENZIMIDAZOLES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; RAF KINASES; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71349084002     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.10.008     Document Type: Article

References (44)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Yamamoto J., Kosuge T., Takayama T., Shimada K., Yamasaki S., Ozaki H., et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 83 (1996) 1219-1222
3. Lai E.C., Fan S.T., Lo C.M., Chu K.M., Liu C.L., and Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221 (1995) 291-298
4. Takenaka K., Kawahara N., Yamamoto K., Kajiyama K., Maeda T., Itasaka H., et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 131 (1996) 71-76
5. Huynh H., Do P.T., Nguyen T.H., Chow P., Tan P.H., Quach T.H., et al. Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int J Oncol 25 (2004) 1839-1847
6. Huynh H., Nguyen T.T., Chow P.K., Tan P.H., Soo K.C., and Tran E. Over-expression of MEK-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis. BMC Gastroenterol 3 (2003) 19
7. Osada S., Kanematsu M., Imai H., Goshima S., and Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg 201 (2005) 405-411
8. Wiesenauer C.A., Yip-Schneider M.T., Wang Y., and Schmidt C.M. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 198 (2004) 410-421
9. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 (2003) 706-712
10. Hwang Y.H., Choi J.Y., Kim S., Chung E.S., Kim T., Koh S.S., et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 29 (2004) 113-121
11. Schmitz K.J., Wohlschlaeger J., Lang H., Sotiropoulos G.C., Malago M., Steveling K., et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48 (2008) 83-90
12. Moon W.S., Rhyu K.H., Kang M.J., Lee D.G., Yu H.C., Yeum J.H., et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?. Mod Pathol 16 (2003) 552-557
13. Thomas M.B., and Abbruzzese J.L. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23 (2005) 8093-8108
14. Jinno K., Tanimizu M., Hyodo I., Nishikawa Y., Hosokawa Y., Doi T., et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 33 (1998) 376-382
15. Tran J., Rak J., Sheehan C., Saibil S.D., LaCasse E., Korneluk R.G., et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264 (1999) 781-788
16. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15 (2004) 275-286
17. Bergers G., Song S., Meyer-Morse N., Bergsland E., and Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
18. Huynh H., Chow P., Palanisamy N., Salto-Tellez M., Goh B.C., Lee C.K., et al. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Hepatol 49 (2008) 52-60
19. Huynh H., Ngo V.C., Fargnoli J., Ayers M., Soo K.C., Koong H.N., et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14 (2008) 6146-6153
20. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
21. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
22. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009) 25-34
23. Huynh H., Chow P., Soo K.C., Toh H.C., Choo S.P., Foo K.F., et al. RAD001 (Everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 13 (2009) 1371-1380
24. Huynh H., Soo K.C., Chow P.K., Panasci L., and Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 12 (2006) 4306-4314
25. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009; Feb 9 [Epub ahead of print].
26. Vaira V., Lee C.W., Goel H.L., Bosari S., Languino L.R., and Altieri D.C. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 26 (2007) 2678-2684
27. Huynh H., Soo K.C., Chow P., and Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther 6 (2007) 138-146
28. Huynh H., Chow P., and Soo K.C. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 6 (2007) 2468-2476
29. Budhu A., Forgues M., Ye Q.H., Jia H.L., He P., Zanetti K.A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10 (2006) 99-111
30. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
31. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118 (2008) 3065-3074
32. Dhillon A.S., Meikle S., Yazici Z., Eulitz M., and Kolch W. Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J 21 (2002) 64-71
33. Hall-Jackson C.A., Goedert M., Hedge P., and Cohen P. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 18 (1999) 2047-2054
34. Hall-Jackson C.A., Eyers P.A., Cohen P., Goedert M., Boyle F.T., Hewitt N., et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6 (1999) 559-568
35. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. MTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res 66 (2006) 1500-1508
36. Kohno M., and Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 38 (2006) 200-211
37. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., and Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27 (2007) 55-76
38. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
39. Graf K., Xi X.P., Yang D., Fleck E., Hsueh W.A., and Law R.E. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 29 (1997) 334-339
40. Hellstrom M., Gerhardt H., Kalen M., Li X., Eriksson U., Wolburg H., et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 153 (2001) 543-553
41. Guo P., Hu B., Gu W., Xu L., Wang D., Huang H.J., et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162 (2003) 1083-1093
42. Bouillet P., Purton J.F., Godfrey D.I., Zhang L.C., Coultas L., Puthalakath H., et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415 (2002) 922-926
43. Whitfield J., Neame S.J., Paquet L., Bernard O., and Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 29 (2001) 629-643
44. Ley R., Balmanno K., Hadfield K., Weston C., and Cook S.J. Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278 (2003) 18811-18816